Efficacy of Olaparib in Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA
Clin. Cancer Res 2022 Nov 01;[EPub Ahead of Print], N Matsubara, J de Bono, D Olmos, G Procopio, S Kawakami, Y Ürün, R van Alphen, A Flechon, MA Carducci, YD Choi, SJ Hotte, E Korbenfeld, G Kramer, N Agarwal, KN Chi, S Dearden, C Gresty, J Kang, C Poehlein, EA Harrington, M HussainFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.